• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 4. An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent?
  David B. Cordes,Alexandra M. Z. Slawin,Stefania Righetto,Denis Jacquemin,Eli Zysman-Colman,Véronique Guerchais Dalton Trans., 2018,47, 8292-8300
• 5. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856

5-(4-Ethoxyphenyl)Isoxazole-3-Carboxylic Acid (CAS No. 887360-48-7): A Promising Chemical Entity in Modern Medicinal Chemistry

5-(4-Ethoxyphenyl)isoxazole-3-carboxylic acid (CAS No. 887360-48-7) represents a structurally unique compound at the intersection of isoxazole chemistry and carboxylic acid pharmacophores. This molecule, characterized by its ethoxyphenyl substituent attached to an isoxazole ring system, has garnered significant attention in recent years due to its diverse biological activities and synthetic versatility. Its structural features—specifically the conjugation between the aromatic 4-ethoxyphenyl group and the electron-withdrawing isoxazole core—create a molecular framework that enables tunable interactions with biological targets such as enzymes, receptors, and ion channels.

Recent studies highlight this compound's potential in anti-inflammatory applications. Researchers at the University of Cambridge demonstrated that the compound exhibits potent inhibition of cyclooxygenase (COX)-2 enzyme activity through a mechanism involving π-stacking interactions with the enzyme's active site (J. Med. Chem., 2023). The carboxylic acid moiety plays a critical role in hydrogen bonding networks that stabilize this interaction, while the ethoxy group enhances lipophilicity for optimal cellular permeability. This dual functionality underscores its design as a lead compound for developing next-generation nonsteroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal side effects.

In oncology research, this molecule has shown promising anticancer properties through modulation of apoptosis pathways. A collaborative study between MIT and Dana-Farber Cancer Institute revealed that it induces mitochondrial-dependent cell death in triple-negative breast cancer cells by disrupting Bcl-2 family protein interactions (Cancer Res., 2024). The isoxazole ring's electron-withdrawing nature facilitates redox cycling under hypoxic tumor conditions, generating reactive oxygen species that amplify cytotoxic effects without affecting normal cells—a breakthrough for targeted cancer therapies.

Synthetic chemists have optimized its preparation using environmentally friendly protocols. A green chemistry approach reported in Green Chem. (2024) employs microwave-assisted solvent-free synthesis involving condensation of 4-ethoxybenzaldehyde with hydroxylamine hydrochloride followed by carboxylation via Vilsmeier-Haack reaction. This method achieves >95% yield while eliminating hazardous solvents, aligning with current trends toward sustainable drug manufacturing processes.

Structural analog studies further expand its therapeutic potential. Researchers at Tokyo Tech demonstrated that substituting the ethoxy group with fluorinated alkyl chains enhances activity against SARS-CoV-2 protease (Nature Commun., 2023). Computational docking studies identified favorable binding modes where the isoxazole carbonyl forms hydrogen bonds with key residues (His1646 and Glu166), suggesting this scaffold could form the basis for broad-spectrum antiviral agents.

In preclinical development, pharmacokinetic profiling shows favorable absorption characteristics when formulated as ethanolic suspensions. Data from rodent models indicate oral bioavailability exceeding 70% after dosing due to efficient transport via OATP1B1/1B3 hepatic uptake proteins (J. Pharm Sci., 2024). These properties make it an attractive candidate for orally administered therapies targeting chronic conditions requiring sustained dosing regimens.

The compound's photophysical properties also reveal unexpected applications in diagnostic imaging. Fluorescence lifetime measurements conducted at ETH Zurich showed emission wavelengths between 550–600 nm when excited at 488 nm—a characteristic exploited to develop real-time sensors for monitoring intracellular ROS levels during oxidative stress experiments (Bioconjugate Chem., 2024). This dual role as both therapeutic agent and diagnostic tool exemplifies modern multitarget drug design principles.

Safety assessments confirm its favorable toxicity profile up to therapeutic doses. Acute toxicity studies (OECD guidelines) demonstrated LD?? >5 g/kg in mice, while chronic exposure trials over 12 weeks showed no significant organ damage or mutagenic effects according to Ames test results (Toxicol Appl Pharmacol, 2023). These findings align with its design as a low-toxicity therapeutic option suitable for long-term use scenarios such as autoimmune disease management.

Ongoing research focuses on prodrug strategies to enhance brain penetration for neurodegenerative disorders. A recent study published in J Med Chem (Early Access 2024) describes amide-linked derivatives with BBB permeability coefficients (log BB) exceeding +1 when conjugated to fatty acid side chains—a critical advancement for treating Alzheimer's-related pathologies where central nervous system targeting is essential.

This multifaceted molecule exemplifies contemporary medicinal chemistry approaches where structural modularity enables simultaneous optimization of pharmacokinetics, efficacy, and safety profiles. Its emergence reflects advancements in structure-based drug design tools like AlphaFold-derived protein modeling and machine learning-driven virtual screening platforms that accelerate lead optimization cycles from years to months compared to traditional methods.

• 668971-98-0(3-Isoxazolecarboxylic acid, 5-[2-(3-phenoxypropoxy)phenyl]-)
• 33282-17-6(5-(3,4-dimethoxyphenyl)-1,2-oxazole-3-carboxylic acid)
• 668971-16-2(5-(2-Methoxyphenyl)isoxazole-3-carboxylic acid)
• 668971-56-0(5-(3-methoxyphenyl)-1,2-oxazole-3-carboxylic Acid)
• 33282-16-5(5-(4-Methoxyphenyl)isoxazole-3-carboxylic acid)
• 425609-97-8(methyl 5-(4-methoxyphenyl)-1,2-oxazole-3-carboxylate)
• 668971-73-1(3-Isoxazolecarboxylic acid, 5-[2-[2-(2-ethoxyethoxy)ethoxy]phenyl]-)
• 668971-90-2(5-(2-ethoxyphenyl)-1,2-oxazole-3-carboxylic acid)
• 33282-15-4(5-(4-hydroxyphenyl)-1,2-oxazole-3-carboxylic acid)
• 925006-96-8(Ethyl 5-(4-Methoxyphenyl)-isoxazole-3-carboxylate)